Episode 23: Artificial Intelligence with Amazon Practice Manager Aziz Nazha

Episode 23: Artificial Intelligence with Amazon Practice Manager Aziz Nazha

Aziz Nazha, MD, former hem/onc at Cleveland Clinic, self-taught computer science expert, and now practice manager in the Data and Machine Learning Team at Amazon Web Services, joins the show to discuss artificial intelligence (AI) and machine learning from an entirely unique perspective. He details the pitfalls of unstructured healthcare data, privacy and ownership issues related to healthcare data and whether hospitals should be allowed to sell their patient data, why AI lagged in the healthcare industry compared to other industries, whether AI will ultimately replace physicians, and many other topics.

Related Resources

N/A

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More